Abbott Laboratories
ABT
$105.90
-$0.02-0.02%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -8.12% | -11.26% | -11.68% | -6.76% | 1.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.12% | -11.26% | -11.68% | -6.76% | 1.34% |
| Cost of Revenue | -6.03% | -4.89% | -3.71% | 1.34% | 8.54% |
| Gross Profit | -9.74% | -15.85% | -17.21% | -12.34% | -3.62% |
| SG&A Expenses | -2.71% | -3.04% | -3.40% | -3.17% | -2.75% |
| Depreciation & Amortization | -2.33% | -2.46% | -3.41% | -2.83% | -1.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.63% | -4.64% | -3.54% | -0.74% | 3.50% |
| Operating Income | -21.35% | -33.54% | -37.07% | -26.17% | -6.08% |
| Income Before Tax | -19.77% | -33.54% | -37.54% | -22.69% | 1.16% |
| Income Tax Expenses | -31.46% | -27.88% | -25.37% | -9.93% | 20.44% |
| Earnings from Continuing Operations | -17.45% | -34.57% | -39.67% | -24.87% | -1.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.45% | -34.57% | -39.67% | -24.87% | -1.95% |
| EBIT | -21.35% | -33.54% | -37.07% | -26.17% | -6.08% |
| EBITDA | -15.91% | -26.11% | -29.42% | -21.02% | -6.50% |
| EPS Basic | -16.77% | -33.80% | -38.95% | -23.95% | -0.74% |
| Normalized Basic EPS | -20.57% | -31.73% | -35.63% | -25.11% | -4.50% |
| EPS Diluted | -16.57% | -33.72% | -38.91% | -23.76% | -0.89% |
| Normalized Diluted EPS | -20.47% | -31.69% | -35.57% | -25.06% | -4.47% |
| Average Basic Shares Outstanding | -0.77% | -1.08% | -1.18% | -1.34% | -1.26% |
| Average Diluted Shares Outstanding | -0.84% | -1.15% | -1.28% | -1.46% | -1.37% |
| Dividend Per Share | 8.33% | 8.51% | 7.53% | 6.52% | 5.49% |
| Payout Ratio | 0.30% | 0.62% | 0.74% | 0.39% | 0.05% |
